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Purpose. To investigate the role of choroidal thickness evaluation with spectral domain optical coherence tomography (SDOCT)
and enhanced depth imaging (EDI) technique in the management of patients with Graves’ disease and orbitopathy (GO).
Methods. Thirty-six eyes of 18 patients with GO and 36 eyes of 18 age-matched control subjects were included in this
retrospective observational study. All the subjects underwent a complete ophthalmological evaluation, including clinical activity
score (CAS) and exophthalmometry. The SDOCT images of the choroid were obtained by EDI modality. Results. Choroidal
thickness was significantly increased in GO than in control eyes (p < 0 01). A significant correlation was found between
choroidal thickness and CAS, proptosis, and the duration of disease (p < 0 05). Conclusion. This study shows that choroidal
thickness, evaluated with EDI-OCT, is significantly increased in patients with GO and correlates with the activity of the disease,
proptosis, and duration of the disease. The choroidal thickening may reflect the ocular hemodynamic changes, and enhanced
depth imaging optical coherence tomography may be a useful tool for the evaluation of orbital congestion and management of
patients with Graves’ disease and orbital involvement.
1. Introduction
Graves’ disease represents the most common cause of
hyperthyroidism in adults. Orbital involvement is known as
Graves’ orbitopathy (GO) [1, 2]. The pathogenetic mecha-
nisms of GO have not yet been fully resolved [3]. It is known
that antibodies against the thyroid-stimulating hormone
(TSH) receptors play an important role. TSH receptors can
not only be found in the thyroid but also in the extraocular
eye muscles and retrobulbar fat tissues. It is thought that
circulating TSH receptor autoantibodies (TRAbs) trigger
inflammation and activation of orbital fibroblasts leading to
intraorbital swelling in an early active stage and, subse-
quently, to fibrosis at a later stage [4–6]. Active GO is charac-
terized by an inflammatory response which may involve the
ocular surface, extraocular muscles, and other orbital tissue.
Depending on the site of inflammation, the disease may
cause dry eye symptoms or conjunctival chemosis, while
the increased orbital volume may cause proptosis and eye
movement disorders [2, 7].
The pathogenesis of the acute inflammatory stage has
been attributed to autoimmunity, but a number of clinical
and experimental studies suggest that superior orbital vein
congestion also plays an important role in the disease inflam-
matory staging and contributes to the development of clinical
signs and symptoms (e.g., proptosis, muscle restriction,
periorbital swelling, and chemosis) during the active stage
of the disease [8–10]. These hemodynamic changes in orbital
vessels can be observed by the orbital color Doppler exami-
nation; however, it is rarely performed, due to its poor
reproducibility and repeatability [8–11]. As a consequence,
novel diagnostic techniques able to assess orbital congestion
are highly sought after. A prompt diagnosis and staging of
disease activity and severity are mandatory to drive therapeu-
tic approach and standardized management of GO. Recent
evidence suggests that spectral domain optical coherence
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tomography (SDOCT) examination may represent a useful,
safe, and rapid diagnostic tool to evaluate GO activity
[12, 13]. SDOCT has been recently developed to assess retinal
and optic nerve morphology and to quantify thickness of
choroidal vascularization by using the enhanced depth imag-
ing (EDI) method [14]. The choroid is primarily a vascular
structure that supplies oxygen and nutrients to the outer
retina. The choroidal veins drain in the ophthalmic veins
and are devoid of the valve; therefore, systemic conditions
that affect blood flow in the ophthalmic veins may influence
the choroidal thickening [15]. Several evidence showed
changes of choroidal thickness during physiological varia-
tions and in a wide range of systemic conditions including
inflammatory and vascular diseases such as Vogt Koyanagi
Harada, Behçet syndrome, sarcoidosis, and migraine [16, 17].
The aim of this study is to evaluate changes of choroidal
thickness in patients with Graves’ disease and orbitopathy
and their relationship with clinical features and activity of
the disease.
2. Patients and Methods
2.1. Study Design. Eighteen consecutive patients with diagno-
sis of Graves’ disease and orbitopathy were included in this
retrospective study at the Department of Sense Organs of
the University Sapienza of Rome. Eighteen healthy, age-
matched volunteers were enrolled among the unaffected
companions of patients attending the outpatients’ service
of the Eye Clinic of the University of Rome “Sapienza”.
Informed consent was obtained from all subjects involved
in the study and the Local Ethics Committee approved the
experimental protocol. The research followed the tenets of
the Declaration of Helsinki.
All subjects were previously examined by an endocri-
nologist, and the laboratory diagnosis of Graves’ disease
was based on the finding of undetectable serum TSH
and high blood thyroid hormone associated with the pres-
ence of circulating antibodies (TRAb). Clinical history was
collected, and all patients underwent a complete eye exami-
nation including (i) exophthalmometry with Hertel instru-
ment (Figure 1), (ii) measurement of eyelid aperture,
(iii) assessment of subjective diplopia using Gorman score
(0: no diplopia, 1: intermittent diplopia, 2: inconstant diplo-
pia, and 3: constant diplopia) [7], (iv) measurement of visual
acuity, (v) assessment of corneal status, (vi) fundus examina-
tion, (vii) ocular biometry (IOL Master, Carl Zeiss Meditec,
Dublin, CA), and (viii) OCT.
Patients were included if they met the following criteria:
(i) age 18 years or more, (ii) diagnosis of Graves’ disease in
the last 12 months, (iii) euthyroid in treatment with anti-
thyroid drugs, and (iv) first episode of GO. All patients
and controls included in this study did not use systemic
steroids. To ensure reliable choroidal thickness assessment
by SDOCT-EDI, all women were evaluated in the first
week after menstruation and all patients with conditions
associated with choroidal changes were excluded including
refractive error>± 3 spherical equivalent; axial length<
22mm and >26mm; intraocular pressure> 18mmHg, cup/
disc ratio> 0.5; any other systemic disease; any other ocular
disease, such as glaucoma, uveitis, or central serous chor-
ioretinopathy; history of uveitis or central serous chorior-
etinopathy; previous intraocular surgery; use of topical
medication or systemic therapy with known interference
on choroidal thickness such as steroids and diuretics;
and low quality (<20units) OCT images.
The activity of GO was assessed through the clinical
activity score (CAS), [18, 19]. According to the EUGOGO
(European Group of Graves’ Orbitopathy) guidelines,
patients were divided into nonactive GO (CAS< 3) and
active GO (CAS≥ 3). The severity of GO was also assessed
based on these guidelines and rated as mild, moderate to
severe, and sight threatening (very severe).
2.2. Optical Coherence Tomography. Included patients and
controls underwent optical coherence tomography (OCT)
examination using the Heidelberg Spectralis (Spectralis
Family Acquisition Module, V 5.1.6.0; Heidelberg Engineer-
ing, Heidelberg, Germany) with Heidelberg Eye Explorer
(V 1.7.1.0; Heidelberg). The SDOCT images of the choroid
were obtained by enhanced depth imaging modality, follow-
ing a standardized protocol described elsewhere [20]. In
brief, two high-quality 30° horizontal and vertical line scans
through the fovea with 90 to 100 frames averaged for each
scan were obtained for each eye and the image with the best
visualization of the border between the choroid and sclera
was used. Choroidal thickness was measured using the
manual caliper tool provided with the software of the OCT
device. The choroid was defined as the layer between the base
of the RPE and the hyperreflective line or margin corre-
sponding to the chorioscleral interface (Figure 2).
The subfoveal choroidal thickness from the horizontal
and vertical line scans was measured by 2 physicians (Magda
Gharbiya and Lucia Restivo) who were masked to the
subjects’ diagnosis, and values were averaged.
(a) (b)
Figure 1: Patient with Graves’ disease and orbitopathy showing a severe proptosis (a) as assessed by Hertel exophthalmometry (b).
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2.3. Statistical Analysis. Statistical analysis was performed
with the SPSS for Windows (V 17.0, SPSS, Chicago, IL,
USA). Normal distribution of data was analyzed by the
Kolmogorov–Smirnov test. Parametric variables were com-
pared using the unpaired t-test. Levene’s test was used to
verify variance homogeneity. Nonparametric distributed
values were analyzed by the Mann–WhitneyU rank sum test.
Categorical variables were compared using Fisher’s exact test.
OCT measurements between groups were compared using
the general linear model, including age, gender, axial length,
and smoking as covariates. Interobserver repeatability for
choroidal thickness measurements was tested with the intra-
class test/retest correlation. We followed the methods of
Häner et al. [21].
Bivariate relationships were evaluated by the Spearman
coefficient or the Pearson analysis as appropriate. Data are
reported as mean values± standard deviation. p values of less
than 0.05 were considered as statistically significant.
3. Results
Thirty-six eyes of 18 patients (mean age, 44.1± 9.8 years;
range, 24 to 57 years; 10 women and 8 men) with a diagnosis
of GO and 36 eyes of 18 age-matched control subjects (mean
age, 44.2± 10.7 years; range, 26 to 60 years; 11 women and
7 men; p > 0 05 for age and sex) were consecutively
included in this study.
Demographic and clinical characteristics of the patients
with GO and control subjects are summarized in Table 1.
In the patients’ group, the mean duration of Graves’
disease was 8.9± 2.0 (range, 5 to 12 months). Eight (55.6%)
out of 18 patients had diplopia. The exophthalmometry
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Figure 2: Optical coherence tomography scan showing the retinal layers and the macular choroidal thickness in a normal eye.
Table 1: GO patients versus controls: demographics and baseline clinical characteristics.
Variable GO patients Controls p value
Age (years) 44.1± 9.8 44.2± 10.7 1.0∗
Gender (male/female) 8/10 7/11 1.0§
Axial length (mm) 23.9± 0.8 24.0± 1.4 0.7∗
Spherical equivalent (diopters) −0.6± 1.3 −0.4± 1.7 0.5°
Intraocular pressure (mmHg) 14.0± 1.9 13.4± 1.6 0.2°
BCVA (number of ETDRS letters) 61.9± 2.3 62.3± 2.1 0.4∗
Glycaemia (mg/dL) 80.8± 5.6 82.4± 6.3 0.4∗
LDL cholesterol (mg/dL) 82.2± 12.4 81.9± 11.9 0.9∗
Total cholesterol (mg/dL) 139.6± 13.3 132.2± 12.9 0.1∗
Systolic blood pressure (mmHg) 123.9± 7.1 122.8± 6.7 0.6°
Diastolic blood pressure (mmHg) 71.6± 4.2 70.8± 4.3 0.6°
Smoking/no smoking 12/6 9/9 0.5§
Values are mean ± SD unless otherwise indicated. ∗Unpaired t-test with Levene’s test for equality of variances. °Mann–Whitney U test. §Fisher’s exact test.
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measurements ranged from 14 to 26mm (mean± SD,
20.1± 3.6mm). According to the severity assessment, 10
(44.4%) patients had a mild GO, and 8 patients had a moder-
ate to severe disease. No patient showed a sight-threatening
GO. The CAS score was <3 in 10 patients and ≥3 in the
remaining 8 patients.
The subfoveal choroid was significantly thicker in GO
than in control eyes (399.2± 84.1μm versus 344.5± 88.1μm,
respectively; F = 9 6, p = 0 003, adjusted for age, gender,
axial length, and smoking) (Figure 3). The interexaminer
correlation coefficients for the subfoveal choroidal thickness
measurements were 0.98 (95% CI, 0.97–0.99).
Correlation analysis in the GO group showed a signifi-
cant direct correlation between choroidal thickness and
disease activity score (CAS) (r = 0 40, p = 0 02) as well as
with the proptosis assessment with Hertel exophthalmome-
try (r = 0 36, p = 0 03). In patients with CAS≥ 3, choroidal
thickness was significantly increased than in the group with
CAS< 3 (436.2± 97.5μm versus 369.6± 89.3μm, respec-
tively, p = 0 02). Furthermore, choroidal thickness was nega-
tively correlated with disease duration (r = −0 43, p = 0 008).
No significant correlation was observed between choroidal
thickness and habit of smoking, diplopia, or severity grading
of GO.
4. Discussion
In this study, using newer generation, high-resolution,
spectral domain OCT and EDI technique, we noninvasively
assessed choroidal thickness change in a cohort of 18 GO
patients. This study confirmed the previous studies reporting
a significant increase in choroidal thickness in patients with
GO when compared with healthy controls. In line with the
other reports, we also found that choroidal thickness corre-
lates with the clinical activity of GO (CAS score). In contrast
with Ozkan et al., our data showed that the higher choroidal
thickness in GO patients was significantly related with more
severe proptosis. This finding may reflect the hemodynamics
alterations of ophthalmic veins associated with orbital con-
gestion. Indeed, increasing evidence suggests that ophthalmic
vein congestion plays a significant role in the pathogenesis of
the active stage of GO [9–11, 22]. A venous stasis has been
described in several previous studies using color Doppler
imaging, and a negative correlation has been found between
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Figure 3: Subfoveal choroidal thickness measured by EDI SDOCT in a patient with Graves’ orbitopathy (a, b) and in a healthy control (c, d).
The graph (e) shows the significant increase of choroidal thickness (mean± SD) in patients with Graves’ orbitopathy (n = 18) versus controls
(n = 18) (∗p < 0 01).
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orbital blood flow parameters and the clinical activity
scores of the ocular diseases [23]. The choroidal thickening
found in our series is probably due to a reduced choroidal
drainage in the ophthalmic veins and, similar to venous
stasis, it correlates with the disease activity, including the
degree of proptosis.
In our results, we further found a negative correlation
between choroidal thickness and disease duration suggesting
an early involvement of the choroid in the natural history
of GO.
Hence, it is reasonable to speculate that choroidal thick-
ness measurement in patients with GO may be used as an
indirect parameter to estimate the degree of orbital conges-
tion, especially in those patients with subclinical and early
GO manifestations. It is known that orbital color Doppler
imaging (CDI) is characterized by several limitations that
may affect orbital congestion (i.e., difficulties in detecting
retrobulbar vessels, the pressure applied on the globe may
decrease flow velocity, and minimal lid and eye movements
may cause artificial color noise) [23, 24]. In contrast, OCT
is a noninvasive, no contact technique that may potentially
overcome these aforementioned CDI-related limits.
The main limitations of the present study are the small
sample size and that choroidal analysis was based on subjec-
tive, nonautomated measurements. Further investigations
are needed to establish the diagnostic and prognostic role
of OCT analysis of choroidal thickness in appropriate
long-term follow-up of a larger GO population.
5. Conclusion
In conclusion, our results suggest a potential role of OCT
choroidal thickness measurement in estimating the degree
of orbital congestion in GO. In fact, choroidal thickness
was significantly higher in patients with active and early
GO and higher proptosis values. The noninvasive, no contact
imaging modality of OCT is easily accessible and may enable
the clinician to detect the retrobulbar GO involvement, even
in those patients with subclinical manifestations and/or at
the beginning of the disease.
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